Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| We have strong contributions from our satellite Lucid test centers and our high volume check your food tube testing events, and we're gaining traction with several important strategic accounts |
| Other strategic accomplishments are that we recently upgraded our revenue cycle management infrastructure and processes as we announced in the last quarter, and the early results of that have continued and are delivering really solid results with EsoGuard claims processing and payments |
| These improvements are related to the cost control initiatives we put in place at the beginning of the year with continued improvement in each successive quarter |
| We have active strategic discussions with large academic medical centers and feel there's great promise there |
| I'll just point out the steady test volume growth, which represents eight consecutive quarters or two full years of quarter-on-quarter growth to [2575] (ph) and represents – and indicate, as shown here, that we still have substantial laboratory manufacturing capacity, which is currently over 10,000 tests per quarter |
| Briefly, quarterly EsoGuard test volume grew 17% and quarterly revenue growth increased 376% |
| Our revenue cycle management upgrades has demonstrated solid progress in the first full quarter reporting |
| And finally, as we announced this week, EsoGuard 2.0 is launched with potential -- with clear benefits in performance as well as in the per sample assay costs |
| As we announced this week, our EsoGuard 2.0 assay has been launched in our laboratory in Orange County, California, with improved performance and lower costs |
| And as I said, it's going extremely well |
| There are ones in there that are -- where we've made enormous progress, working up through the C-suite, getting people to sign off on, and we think we're making excellent progress to actually consummating, and there are others that are more in -- more early stages of the discussion |
| The opportunity to improve patient outcomes, increase workflow efficiency, and lower costs results in a substantial market opportunity |
| The business model is very attractive |
| So there's a strong -- there's an immediate opportunity and there's a strong motivation commercially for them to collect that data quickly and collect data in a way that maximizes the likelihood that they'll hit the safety benchmarks |
| So really, we think it's a great opportunity, and it's one that we think will benefit for modern digital health tools such as our platform |
| We've had a very substantial boost to our clinical utility data to support in-network payer coverage engagement |
| As we introduced in our last call, there's a separate opportunity, the Bio Pharma opportunity that we're very excited about and we are aggressively pursuing |
| The numbers are quite impressive |
| Really excited about this past quarter for PAVmed and its subsidiaries, particularly the strong quarter that Lucid Added |
| If you were to normalize the loss by adding back the effect of the net convertible debt expenses, the GAAP EPS improved by $0.2 year-over-year for the quarter and improved $0.27 year-over-year for the year to date |
| It also provides Veris with additional revenue opportunities through enhanced technical support and charging for clinical integration, clinical support such as our in coverage, as well as revenue opportunities directly derived from the implantable device |
| And so, by having the practice have the opportunity to be on a platform that facilitates the participation in this post-market surveillance phase is a win for the practice as well |
| And finally, as I mentioned, we're very excited to be making solid progress on the Veris implantable monitor |
| Once we have this in place, it will really be a game changer for the platform as it assures 100% patient compliance with the remote patient monitoring billing requirements and really provides a substantial added value both on the clinical care side as well as the economics for the medical -- for the practice and the institution |
| And we're very excited about a couple of leads here which we hope to consummate into active accounts in the near term |
| There's also and significant opportunity -- commercial opportunity with the practices which is not really the case in the pre-submission phases of this, which is that, with these new drugs CAR-T and others the practices that's actually quite lucrative for a practice to administer that and practices are seek to be certified to administer this, which is important for their bottom line and for their patients to get access to this |
| I will also note, as I have in recent calls, we remain very active on the business development side since current market conditions offer a plethora of high-value assets which may provide real opportunities to enhance PAVmed shareholder values |
| The year-over-year OpEx comparison shows an improvement in OpEx by about 30% for each of the GAAP and non-GAAP measures, a direct reflection of the cost controls we put in place the beginning of the year |
| So, a lot of those kinks have now been worked out, and we've had, as I mentioned, good feedback from the two practices were really -- heavily engaged in this and helping us with working out all those kinks |
| We have had multiple successful FDA pre-submission meetings, seeking feedback on all these various design features, and those have all gone extremely well, and we're progressing towards FDA submission and commercial launch next year |
| Statement |
|---|
| Furthermore, as cash collections continue to accelerate, as we will talk about in a second, This can further throttle the burn rate for the upcoming quarters |
| As you'll see in our 10-Q, this is called Variable Consideration, the jargon of GAAP’s ASC 606 Revenue Recognition Guidelines, and presently there is insufficient predictive data to recognize revenue when invoiced |
| Frank Takkinen I apologize |
| There are significant periods of market surveillance |
| And 20% of these unplanned admissions are likely preventable |
| So as anybody who's paying attention knows, there's been a boon, really almost a revolution that's going on right now in oncology therapeutics |
Please consider a small donation if you think this website provides you with relevant information